Serum Concentrations of Granulocyte Colony-Stimulating Factor (G-CSF) in Antithyroid Drug-Induced Agranulocytosis

Yasuhiro MURAKAMI, Ichiro SASAKI, Tetsuya HIRAIWA, Takeshi ARISHIMA, Mitsuru ITO, Toshiaki HANAFUSA, Sadaki SAKANE, Nakaaki OHSAWA, Junta TAKAMATSU, Akira MIYAUCHI, Kanji KUMA
2004 Endocrine journal  
Granulocyte colony-stimulating factor (G-CSF) levels in serum were determined by a highly-sensitive chemiluminescent enzyme immunoassay (limit of detection, 0.5 pg/ml) in 54 patients with Graves' disease including 6 patients complicated with methimazole-induced agranulocytosis. Serum G-CSF levels in patients with Graves' disease were not different from normal subjects and did not correlate with serum FT 4 level or circulating neutrophil counts. Before the onset of agranulocytosis, there was no
more » ... osis, there was no difference in serum G-CSF level between the patients complicated with agranulocytosis and the uncomplicated patients. When circulating neutrophil counts decreased to less than 0.5 × 10 9 /L, serum G-CSF level elevated with the mean of 106.8 ± 82.2 (SD) pg/ml, but the level did not correlate with the duration of agranulocytosis. Interestingly, maximum serum G-CSF level during the treatment with recombinant human G-CSF (100 mg/day) was related to bone marrow finding at the onset of agranulocytosis and correlated with the duration of agranulocytosis (r = 0.824, p<0.05). In conclusion, measuring serum G-CSF levels with a highly-sensitive chemiluminescent enzyme immunoassay revealed that 1) thyrotoxicosis does not affect serum G-CSF level, 2) serum G-CSF level during antithyroid drug treatment does not play an important role in development of agranulocytosis, 3) the maximum serum G-CSF level in the course of agranulocytosis is related to the responsiveness of bone marrow to G-CSF and the recovery time from agranulocytosis.
doi:10.1507/endocrj.51.579 pmid:15644577 fatcat:qozarcl5szbprphh3uonmvlqeq